Waterfront Wealth Inc. Has $1.17 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Waterfront Wealth Inc. lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 44.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 15,865 shares of the medical research company’s stock after purchasing an additional 4,899 shares during the quarter. Waterfront Wealth Inc.’s holdings in Edwards Lifesciences were worth $1,174,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP raised its stake in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. Jennison Associates LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth $555,939,000. Assenagon Asset Management S.A. increased its holdings in shares of Edwards Lifesciences by 475.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after purchasing an additional 3,506,886 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Edwards Lifesciences by 239.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after acquiring an additional 2,606,950 shares in the last quarter. Finally, Seilern Investment Management Ltd acquired a new stake in Edwards Lifesciences during the fourth quarter worth about $109,490,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Up 0.0 %

Shares of Edwards Lifesciences stock opened at $74.71 on Friday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The stock has a market cap of $44.06 billion, a P/E ratio of 10.72, a P/E/G ratio of 4.89 and a beta of 1.10. The stock’s 50 day simple moving average is $72.86 and its 200-day simple moving average is $69.86. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,489 shares of company stock valued at $2,002,829. 1.29% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on EW. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.